Teva is developing compound for type 1 diabetes

12/19/2011 | Bloomberg

Teva Pharmaceutical Industries plans to use the DiaPep277 compound to develop a treatment that would replace insulin therapy in some patients with type 1 diabetes. In a trial, the drug appeared to promote stable C-peptide levels, an indication of insulin secretion by pancreatic cells, researchers said. The results of a second late-stage trial are expected in 2014.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID